What’s happening in our world?
As a global medical consultancy, our team of experts are dedicated to sharing their expertise and knowledge, to bring excellence to the development and use of pharmaceuticals, for the advancement of human health.
As a global medical consultancy, our team of experts are dedicated to sharing their expertise and knowledge, to bring excellence to the development and use of pharmaceuticals, for the advancement of human health.
The curling wheeze and tight-lipped breathing of inflammatory lung conditions (1), the severe abdominal pain and gastrointestinal disruption of inflammatory bowel disease (IBD) (2), and the arduous stiffness associated with rheumatoid arthritis (RA) (3) are common inflammatory ailments that globally prevail. Though the aetiology of each disease is not well understood, each share a similar…
Ecopharmacovigilance The rate at which modern medicine is progressing is astonishing. Production and usage of medicines across the globe continue to grow substantially. The global pharmaceutical market is estimated to exceed USD 1.5 Trillion in the coming years. No doubt these new medicines have improved quality of life and saved lives for some of the…
Amongst many things, the COVID-19 pandemic questioned our traditional, separated work-home lifestyle divide ingrained over generations. The paradigm shift, to working from home (WFH) promised individuals the return of and flexibility with time – no more commutes, distractions, nor concrete set hours. Initially, this “gift” from COVID provided nuclear families and co-habitants with more time…
A/Prof Adrian Bootes Director of Drug Development & Regulatory Affairs
In a rapidly changing world where technological developments happen on a daily basis, it is only logical that advanced telecommunications and computer technologies are used to improve health care and expand access to health services. The necessity to provide high quality and accessible medical attention was highlighted with the COVID-19 pandemic where interpersonal interactions were…
Physical activity presents as a prevention strategy for numerous chronic health conditions, including coronary heart disease, insulin resistance, hypertension and breast, colon, and endometrial cancer.1 However, for individuals with existing chronic health conditions, evidence is growing to support the integration of regular exercise into their treatment plans. Multiple sclerosis Multiple sclerosis (MS) is a chronic…
What happens when a patient is injured in a clinical trial in Australia, will there be the care necessary to nurse them back to full health or at least to the best that they can be with their condition? Will that care be provided quickly, and will all needs be covered? Currently our understanding rests…
Depression is a complex multifactorial neuropsychiatric condition which is associated with a high burden of disease [1-3]. Depression disturbs mood and cognition resulting in poor functioning and a significant detriment to the quality of life [1, 3-5]. It is one of the most prevalent disorders affecting more than 300 million individuals globally [6]. Five per cent of…
Pleasingly, the world is moving on from solely considering the Drs, Scientists, Regulators and Drug Developers’ opinions in considering what a future patient really needs. The recent ARCS Conference had an outstanding presentation from Ms Gillian Mason, which helped me think more about the needs of the consumer/patient. Extrapolating from what I heard, we need…
On miners and bots – the future of the Medical Affairs DepartmentIt’s 2025 and I would like you to join me in welcoming the new colleagues to the Medical Affairs Department:A data scientist, an AI bot and a digital capabilities specialist. Who are they and how could they enhance the work a Medical Affairs team…
Clinical Development Team Radiopharmaceuticals are radioisotopes that have been bound to biological molecules to target specific cells, organs or tissues. These relatively new drugs are being increasingly used for both the diagnosis and treatment of a number of diseases including: prostate cancer, renal cancer and glioblastoma. These medicines may allow for better diagnosis and more…
Clinical Development Team A revealing final session of the “AusBiotech and Invest 2020” conference addressed the opportunities and risks for the Australian Biotechnology sector. A discussion between diverse industry experts painted an optimistic future for the industry as recent government policy movements have provided a golden opportunity for Australian Biotech to showcase its value. It…
The role of digital health in clinical trials Rose-Marie Pennisi – Pharmaceutical Manager Digital tools and technologies are transforming the way clinical trials are being conducted and creating better engagement with more empowered trial participants and better collaboration between trial sites, clinicians, vendors and sponsors. Not only can these new innovative electronic tools and platforms improve…
Rose-Marie Pennisi – Pharmaceutical Manager With the costs of new product development now estimated to be around $1.4 billion USD, Real World Evidence (RWE) is more important than ever with companies looking for ways to do more with less. RWE) is emerging as invaluable in the clinical evidence landscape and transforming the way we collect clinical…
As Australia’s premier life science conference, AusBiotech brings together all levels of industry to establish and develop client relationships, network with like-minded service providers and build awareness of their unique customer value proposition within the international life sciences community. At this year’s event, My Medical Department had the privilege to connect with many remarkable Australian…